Homoeopathic treatment of fatty liver

Phase 2

Conditions: Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Registration Number: CTRI/2023/03/050323

Lead Sponsor: D N De Homoeopathic Medical College and Hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Open to Recruitment

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1. Patient with grade I and II NAFLD established by ultrasound and altered liver enzyme (serum ALT level >=40 IU/L) [ICD-10 code: K 76.0].

2. Age between 18 and 65 years.

3. Participants of either sex and transgender.

4. Literate patients; ability to read English and/or Bengali and/or Hindi; Illiterate people will be interviewed by the investigators maintaining adequate privacy to fill up the questionnaires.

5. Providing with written informed consent voluntarily to participate.

Exclusion Criteria

1. Regular or excessive use of alcohol and any other addiction.

2. History of chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis).

3. Cholestatic and metabolic liver diseases, hepatic steatosis., hemochromatosis and liver transplants.

4. Combined with uncontrolled diabetes, uncontrolled hypertension, uncontrolled hypothyroidism, kidney or heart disease, stroke or any other severe systemic diseases affecting quality of life.

5. Person under corticosteroid therapy, substance abuse.

6. Vulnerable population â?? unconscious, non-ambulatory, too sick for consultation, differently abled, terminally ill or critically ill, mentally incompetent people.

7. Pregnant and puerperal women and lactating mother.

8. Self-reported immune-compromised state.

9. Already undergoing homoeopathic treatment within last 3 months for any other disease.

10. Simultaneous participation in any other trials.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum ALT levelTimepoint: At baseline and after 3 months

Secondary Outcome Measures

Name	Time	Method
Blood Lipid ProfileTimepoint: At baseline and after 3 months;Chronic Liver Disease Questionnaire (CLDQ)Timepoint: At baseline, and every month, up to 3 months of intervention;Measure Yourself Medical Outcome Profile v2 (MYMOP-2) questionnaireTimepoint: At baseline, and every month, up to 3 months of intervention;Serum AST levelTimepoint: At baseline and after 3 months;USG featuresTimepoint: At baseline and after 3 months